description: Protocols: Genetic modification, ERO1-Lα CRISPR-Cas9 Knock-out MDAMB231 metastatic breast tumors. Collection of 5-10 million cells in PDS, and resuspension of the pellet in a buffer. Paclitaxel was injected intravenously (i.v.) at the dose of 15 mg/kg, Q7x2 (every seven days for 2 weeks) and stopped two weeks before the end of the experiment. ISRIB (trans-isomer, Aurogene s.r.l) was dissolved in 10% DMSO (Sigma-Aldrich) in corn oil. It was injected interaperitoneally (i.p.), at the dose 2.5 mg/kg every two days for three weeks. Forty-eight hours after the last dose of ISRIB, mice were sacrificed, and primary breast tumors were isolated and RNA extracted. Protocol: miRNeasy Mini Kit TruSeq Stranded Total RNA Sample Preparation Guide
attributes.tag: ENA-FIRST-PUBLIC
attributes.value: 2022-06-26
attributes.tag: ENA-LAST-UPDATE
attributes.value: 2022-06-26
attributes.tag: External Id
attributes.value: SAMEA14370844
attributes.tag: INSDC center alias
attributes.value: Istituto di Ricerche Farmacologiche Mario Negri IRCCS
attributes.tag: INSDC center name
attributes.value: Istituto di Ricerche Farmacologiche Mario Negri IRCCS
attributes.tag: INSDC first public
attributes.value: 2022-06-26T00:14:46Z
attributes.tag: INSDC last update
attributes.value: 2022-06-26T00:14:46Z
attributes.tag: INSDC status
attributes.value: public
attributes.tag: Submitter Id
attributes.value: E-MTAB-11313:20_Combo_ERO1_WT_S8_R1_001
attributes.tag: broker name
attributes.value: ArrayExpress
attributes.tag: cell_line
attributes.value: MDAMB231
attributes.tag: common name
attributes.value: human
attributes.tag: disease
attributes.value: breast cancer
attributes.tag: genotype
attributes.value: wild type genotype
attributes.tag: isolate
attributes.value: not applicable
attributes.tag: organism part
attributes.value: mammary gland
attributes.tag: sample name
attributes.value: E-MTAB-11313:20_Combo_ERO1_WT_S8_R1_001